Amersham International of the U.K. will acquire 14.9% of radioisotopesupplier Nordion International. Amersham is a participant in theinvestment group that won bidding last month to buy Nordion fromthe Canadian government. The $165 million (U.S. $144
Amersham International of the U.K. will acquire 14.9% of radioisotopesupplier Nordion International. Amersham is a participant in theinvestment group that won bidding last month to buy Nordion fromthe Canadian government. The $165 million (U.S. $144 million)acquisition remains subject to due diligence prior to a finalclosing.
Nordion was formerly a division of Atomic Energy of CanadaLtd. (AECL). The Canadian government divided AECL into two companiesin 1988 in preparation for its privatization. Nordion is the world'slargest supplier of technetium-99m for use in nuclear medicine,according to W. Paul O'Neill, Nordion president.
The pharmaceutical company also supplies the strontium basefor Squibb's CardioGen, a rubidium-82 imaging agent for positronemission tomography. Squibb and Nordion signed a three-year strontiumsupply agreement last year (SCAN 7/4/90).
The other company formed out of AECL is Theratronics International,a manufacturer of cobalt cancer therapy products, O'Neill said.Both firms are based in Kanata, Ontario.
Theratronics purchased Medical High Technology International,a Clearwater, FL, computed tomography developer, three years ago.MHTI, in turn, bought CT tube developer Meicor last year (SCAN8/29/90).
Canadian divestiture legislation limited foreign ownershipof Nordion to 25%. The lead partner in the winning investmentgroup is MDS Health Group of Etobicoke, Ontario. MDS is an employee-owned,diversified health-care company. It will purchase 80.1% of Nordion.
Among its many medical businesses, MDS operates in vitro diagnostictesting laboratories and nursing homes, provides home-health servicesand develops medical office buildings, according to informationsupplied by the Canadian Ministry of Finance.
The third investment partner, acquiring the remaining 5% ofNordion, is the Terry Fox Medical Research Foundation. This isa charity established to stimulate an industrial biotechnologybase in British Columbia.
Nordion maintains three processing facilities. Both the Kanatasite and Nordion Europe outside Brussels manufacture and marketreactor-produced isotopes, including technetium, and related equipment.A facility in Vancouver, B.C., manufacturers cyclotron-producedradioisotopes.
More than 90% of Nordion's $107 million (U.S. $93 million)in 1990 sales occurred outside of Canada. The firm created NordionEurope last year by acquiring assets of Belgium's Institut Nationaldes Radioelements.
BRIEFLY NOTED:
The Vanguard acquisition will allow Kodak to offer completeimaging systems for the cardiac cath market, said Joseph C. Barry,general manager for cardiology in the film vendor's Health Sciencesdivision.
MRI-Based AI Radiomics Model Offers 'Robust' Prediction of Perineural Invasion in Prostate Cancer
July 26th 2024A model that combines MRI-based deep learning radiomics and clinical factors demonstrated an 84.8 percent ROC AUC and a 92.6 percent precision-recall AUC for predicting perineural invasion in prostate cancer cases.
Breast MRI Study Examines Common Factors with False Negatives and False Positives
July 24th 2024The absence of ipsilateral breast hypervascularity is three times more likely to be associated with false-negative findings on breast MRI and non-mass enhancement lesions have a 4.5-fold likelihood of being linked to false-positive results, according to new research.
Can Polyenergetic Reconstruction Help Resolve Streak Artifacts in Photon Counting CT?
July 22nd 2024New research looking at photon-counting computed tomography (PCCT) demonstrated significantly reduced variation and tracheal air density attenuation with polyenergetic reconstruction in contrast to monoenergetic reconstruction on chest CT.